Tolerance induction by soluble CTLA4 in a mouse skin transplant model.
Tepper
M A
MA
Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121.
Linsley
P S
PS
Tritschler
D
D
Esselstyn
J M
JM
D000069594:Abatacept; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000097:blood; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000097:blood / Q000494:pharmacology*; D060908:CTLA-4 Antigen; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006085:Graft Survival / Q000276:immunology*; D006801:Humans; D018796:Immunoconjugates; D007165:Immunosuppression Therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008815:Mice, Inbred Strains; D011993:Recombinant Fusion Proteins / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology; D016038:Skin Transplantation / Q000276:immunology*; D013997:Time Factors
D000888:Antibodies, Anti-Idiotypic; D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; C556707:Ctla4 protein, mouse; D018796:Immunoconjugates; D011993:Recombinant Fusion Proteins; D000069594:Abatacept